SCHEMBL3076759

SCHEMBL3076759

Cc1cccc(N2CCN(C(=O)CCOc3ccccc3)CC2)c1C

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.89
KMT2A Q03164 7/20 0.89
ALDH1A1 P00352 5/20 0.89
NPC1 O15118 4/20 0.89
RAB9A P51151 3/20 0.89
SMN1; SMN2 Q16637 3/20 0.89
TSHR P16473 2/20 0.89
MAPK1 P28482 1/20 0.89
KDM4E B2RXH2 2/20 0.60
GAA P10253 2/20 0.60
ALOX15 P16050 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MEN1 O00255 6/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 3/20 0.58
PKM P14618 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
TP53 P04637 1/20 0.55
POLB P06746 1/20 0.55
ADAMTS5 Q9UNA0 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082219 0.91 NPC1 (0.74) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL3082105 0.86 NPC1 (0.67) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL30795903 0.83 NPC1 (0.65) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL3081851 0.83 NPC1 (0.65) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL3084950 0.81 NPC1 (0.60) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL8912424 0.80 MAPT (0.72) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL4079406 0.80 MAPT (0.72) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL9987606 0.80 MAPT (0.67) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL3085560 0.80 NPC1 (0.61) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL8916658 0.79 MAPT (0.73) MAPTKMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US claimed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP claimed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO claimed
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US disclosed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP disclosed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227870-A1 Novel Compounds GRM5, GRIK5, GRM1 MAPT 1435/4885KMT2A 2237/4885ALDH1A1 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.